Elena Herrera Carrillo

Associate Professor

Amsterdam UMC Locatie AMC

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Immunology Immunology professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Elena Herrera Carrillo is an Associate Professor at Amsterdam UMC Locatie AMC in the Netherlands. Her research focuses on innovative genomic editing technologies, including CRISPR-Cas systems, and their applications in targeting viral pathogens such as HIV and SARS-CoV-2. She has contributed significantly to the development of antiviral strategies and diagnostic methods, as evidenced by her recent publications in the field.

Articles (15)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Andreas Reuter

Head of Proteomics Core Facility

Paul-Ehrlich-Institut

GERMANY

View details

Christian Buchholz

Paul-Ehrlich-Institut

GERMANY

View details

Luis Enjuanes

Profesor

Centro Nacional de Biotecnología

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Elena Herrera Carrillo

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Evaluation of the effect of RNA secondary structure on Cas13d-mediated target RNA cleavage

A CRISPR-Cas Cure for HIV/AIDS

FcγRIIA-specific DARPins as novel tools in blood cell analysis and platelet aggregation.

Efficient CRISPR-Cas13d-Based Antiviral Strategy to Combat SARS-CoV-2

In-house ELISA protocols for capsid p24 detection of diverse HIV isolates.

AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery.

CRISPR-Cas12b enables a highly efficient attack on HIV proviral DNA in T cell cultures.

A combinatorial CRISPR-Cas12a attack on HIV DNA

SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant

In Silico Prediction and Selection of Target Sequences in the SARS-CoV-2 RNA Genome for an Antiviral Attack

Design and Evaluation of AgoshRNAs with 3'-Terminal HDV Ribozymes to Enhance the Silencing Activity.

Design and Evaluation of Guide RNA Transcripts with a 3'-Terminal HDV Ribozyme to Enhance CRISPR-Based Gene Inactivation.

Engineered miniature H1 promoters with dedicated RNA polymerase II or III activity.

Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a system with only a single crRNA.

CRISPR therapy towards an HIV cure.

Collaborators (3)

Andreas Reuter

Christian Buchholz

Luis Enjuanes

Make your next move.